Green Cross Halts US, Europe GreenGene F Trials To Focus On China

Green Cross has overhauled the global development strategy for its hemophilia A therapy GreenGene F, halting slow-progressing Phase III trials in the US and Europe and shifting its focus instead to the fast-growing China market.

Green Cross Corp. has decided to stop US and European Phase III clinical trials with GreenGene F (beroctocog alfa) for hemophilia A and instead focus on developing the recombinant coagulation Factor VIII product in China after encountering delays in recruiting patients in the US.

The leading South Korean biopharma firm had originally expected the US clinical trial to take two to three years, but...